GLPwatch
Liraglutide.
Nat Rev Drug Discov · 2010
Last updated 2026-05-28In January 2010, the FDA approved liraglutide (sold as Victoza) to help adults with type 2 diabetes improve their blood sugar control. It is an injectable medication that works by mimicking a natural hormone in the body.
AI summary of the abstract below.
| Journal | Nat Rev Drug Discov, 2010 |
|---|---|
| Citations | 144 |
| Relative citation ratio | 3.95 |
| NIH percentile | 89 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction |
Abstract
In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.
Verbatim abstract via PubMed 20357801 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.